- Home
- DNTH vs SNDX Comparison
DNTH vs SNDX Comparison
Compare DNTH & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- SNDX
- Stock Information
- Founded
- DNTH 2015
- SNDX 2005
- Country
- DNTH United States
- SNDX United States
- Employees
- DNTH N/A
- SNDX N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- DNTH Health Care
- SNDX Health Care
- Exchange
- DNTH Nasdaq
- SNDX Nasdaq
- Market Cap
- DNTH 1.5B
- SNDX 1.3B
- IPO Year
- DNTH N/A
- SNDX 2016
- Fundamental
- Price
- DNTH $36.05
- SNDX $15.03
- Analyst Decision
- DNTH Strong Buy
- SNDX Strong Buy
- Analyst Count
- DNTH 11
- SNDX 11
- Target Price
- DNTH $65.22
- SNDX $38.55
- AVG Volume (30 Days)
- DNTH 664.6K
- SNDX 2.2M
- Earning Date
- DNTH 11-06-2025
- SNDX 11-04-2025
- Dividend Yield
- DNTH N/A
- SNDX N/A
- EPS Growth
- DNTH N/A
- SNDX N/A
- EPS
- DNTH N/A
- SNDX N/A
- Revenue
- DNTH $4,854,000.00
- SNDX $77,933,000.00
- Revenue This Year
- DNTH N/A
- SNDX $641.22
- Revenue Next Year
- DNTH N/A
- SNDX $110.64
- P/E Ratio
- DNTH N/A
- SNDX N/A
- Revenue Growth
- DNTH 17.87
- SNDX 2126.66
- 52 Week Low
- DNTH $13.37
- SNDX $8.58
- 52 Week High
- DNTH $40.16
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- DNTH 57.06
- SNDX 44.32
- Support Level
- DNTH $33.34
- SNDX $14.69
- Resistance Level
- DNTH $36.68
- SNDX $15.99
- Average True Range (ATR)
- DNTH 2.11
- SNDX 0.82
- MACD
- DNTH -0.53
- SNDX -0.14
- Stochastic Oscillator
- DNTH 39.74
- SNDX 16.11
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.